MTIP AG: MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
1.4.2021 09:00:00 CEST | news aktuell GmbH | Press release
(Basel, Switzerland): MTIP FUND II, SCSp is MTIP’s second healthtech fund, designed to provide growth capital and build on the healthtech investment thesis of its successful predecessor. With a target size of EUR 200m the fund invests in digital health and connected medical device companies, based primarily in Europe, that offer differentiated solutions for a rapidly evolving healthcare environment.
MTIP’s second fund executed a strong first closing securing EUR 130m. The capital was raised by different investors comprising mainly institutional investors, pension funds, family offices, hospitals, and foundations. The company is proud to work together with the European Investment Fund (EIF) as an anchor investor. EIF’s Chief Executive Alain Godard said: “MTIP’s fund strategy fits with EIF's ambition of financing the vital growth segment of the European Venture Capital ecosystem, which is largely underfunded and overly dependent on non-European investors for larger investments. The EIF is pleased to support MTIP and tackle two major gaps in the European market - digital health and growth capital.”
"This closing is an enormously important milestone in our company history, and we are pleased to have overachieved our expectations. Our Fund II has already added three stellar investments in Oviva, Trialbee and Koa Health to its portfolio with more to come soon. This creates a strong momentum towards the final close", emphasizes Dr. Christoph Kausch, Managing Partner of MTIP. The Fund continues to see a unique flow of investment opportunities, enhanced by the firm’s network, its leading role in Europe, and the strength of its strategy.
About MTIP
MTIP is a fast-growing pan-European healthtech growth capital investor, based in Basel Switzerland. We invest in digital health and digitally connected medical device companies, with offerings that provide clear health-related economic benefits. Our entrepreneurial investment team, which has complementary private equity skills and exceptional deal-making capabilities, actively works with our portfolio companies to boost growth. MTIP efficiently deploys capital to unlock value and generate attractive returns for our investors. Visit www.mtip.ch for more information
Contacts
Dr. Christoph KauschManaging Partner
communications@mtip.chLinks
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Compax MVNE continues to support Airalo’s eSIM platform2.3.2026 14:46:10 CET | Press release
Compax, a leading solution provider in the MVNO and telco space, will continue to support Airalo, the world’s first and largest eSIM platform.
Grünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands2.3.2026 10:39:09 CET | Press release
Grünenthal acquired Kyowa Kirin International’s 49% stake in ‘Grünenthal Meds’, a joint venture formed in 2023 to market the established medicines portfolio from Kyowa Kirin International. Through this acquisition, Grünenthal assumes the sole responsibility of a portfolio comprising 12 brands across six therapeutic areas and >60 markets.
Valle Venia presents new song by LPS feat. Lara: Where will it take me27.2.2026 10:15:00 CET | Press release
The song describes the challenge of trusting the flow, relying on oneself, following one's own values with confidence.
Vyoma awarded ESA data procurement contract for space-based data on small space debris24.2.2026 10:53:34 CET | Press release
(Munich, February 24th, 2026) Vyoma, a Munich-based company providing Space Domain Awareness (SDA) capabilities, has been selected as the winner of the ESA tender on ”Data Procurement for Space-Based Statistical Data on Small Space Debris Phase 1”, funded via ESA‘s Space Safety Programme (S2P). ESA’s Meteoroid And Space debris Terrestrial Environment Reference (MASTER) model provides a description of the space environment around Earth, supporting satellite designers, operators and others with risk assessments. Currently, there exists a significant temporal and spatial knowledge gap for observations of space debris with sizes smaller than the detection limit of ground-based sensors. Vyoma's Flamingo-1 satellite is ideally positioned to generate the image data ESA is seeking. Flying “in-situ” at an altitude of 510 km, Flamingo-1's instrument can monitor large volumes of space at once. This sensor detects objects at long and short distances and captures small and fast objects reliably, im
Medi-Globe Launches mAI Companion® — the World’s First Real Time AI Assistant for Pancreatic EUS, Co Developed with IHU Strasbourg —Now MDR CE Marked and Available for Clinical Use in Europe24.2.2026 10:00:00 CET | Press release
Rohrdorf (Achenmühle), Germany — February 24, 2026 — Medi-Globe today announced the launch of mAI Companion®, a real-time medical AI solution designed to assist physicians in detecting pancreatic lesions during endoscopic ultrasound (EUS) — addressing one of the deadliest and most difficult-to-detect cancers, where earlier identification can dramatically change patient outcomes.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom

